Research ArticleEmerging Technologies and Therapeutics
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study
Khalid A. Jadoon, Stuart H. Ratcliffe, David A. Barrett, E. Louise Thomas, Colin Stott, Jimmy D. Bell, Saoirse E. O’Sullivan, Garry D. Tan
DOI: 10.2337/dc16-0650 Published 1 October 2016
Khalid A. Jadoon
1Division of Medical Sciences & Graduate Entry Medicine, School of Medicine, University of Nottingham, Derby, U.K.
Stuart H. Ratcliffe
2St. Pancras Clinical Research, London, U.K.
David A. Barrett
3School of Pharmacy, Centre for Analytical Bioscience, University of Nottingham, Nottingham, U.K.
E. Louise Thomas
4Department of Life Sciences, Research Centre for Optimal Health, University of Westminster, London, U.K.
Colin Stott
5GW Pharmaceuticals, Cambridge, U.K.
Jimmy D. Bell
4Department of Life Sciences, Research Centre for Optimal Health, University of Westminster, London, U.K.
Saoirse E. O’Sullivan
1Division of Medical Sciences & Graduate Entry Medicine, School of Medicine, University of Nottingham, Derby, U.K.
Garry D. Tan
6NIHR Oxford Biomedical Research Centre, Oxford Centre for Diabetes, Endocrinology & Metabolism, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, U.K.